S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NASDAQ:TBPH

Theravance Biopharma Earnings Date, Estimates & History

$18.92
+0.53 (+2.88 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.12
Now: $18.92
$19.13
50-Day Range
$16.57
MA: $18.59
$20.64
52-Week Range
$14.48
Now: $18.92
$31.35
Volume360,690 shs
Average Volume361,657 shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Earnings

Theravance Biopharma (NASDAQ:TBPH) Earnings Information

Theravance Biopharma last released its quarterly earnings results on February 22nd, 2021. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. Theravance Biopharma has generated ($4.25) earnings per share over the last year. Theravance Biopharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 5th, 2021 based off prior year's report dates.

Theravance Biopharma Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Theravance Biopharma (NASDAQ:TBPH) Earnings Estimates

2021 EPS Consensus Estimate: ($2.71)
2022 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20213($1.10)($0.75)($0.88)
Q2 20213($1.05)($0.67)($0.82)
Q3 20213($1.00)($0.59)($0.78)
Q4 20212($0.65)$0.19($0.23)
Q1 20221($0.31)($0.31)($0.31)
Q2 20221($0.32)($0.32)($0.32)
Q3 20221($0.33)($0.33)($0.33)
Q4 20221($1.00)($1.00)($1.00)

Theravance Biopharma (NASDAQ TBPH) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/5/2021
(Estimated)
       
2/22/202112/31/2020($1.02)($0.92)($0.92)Transcript
11/5/20209/30/2020($0.98)($1.16)($1.16)$17.58 million$18.26 millionListen
8/6/20206/30/2020($0.95)($1.00)($1.00)$21.05 million$15.01 millionTranscript
5/6/20203/31/2020($1.07)($1.40)($0.88)$18.02 million$19.86 millionTranscript
2/24/2020Q4($1.11)($1.17)($1.17)$18.33 million$29.50 millionTranscript
11/5/2019Q3($1.05)($1.05)($1.05)$13.33 million$12.43 millionTranscript
7/31/2019Q2($1.22)($0.72)($0.72)$13.92 million$26.15 millionTranscript
5/7/20193/31/2019($1.18)($1.32)($1.32)$16.45 million$5.34 millionN/A
2/26/2019Q4 2018($1.12)($0.92)($0.92)$12.32 million$15.74 millionN/A
11/6/20189/30/2018($1.18)($1.10)($1.10)$10.55 million$12.84 millionTranscript
8/1/20186/30/2018($1.20)($0.76)($0.76)$9.97 million$23.48 millionN/A
5/8/2018Q1($1.2590)($1.22)($1.22)$5.74 million$8.32 millionN/A
2/27/2018Q4 2017($1.15)($1.64)($1.64)$3.71 million$4.52 millionN/A
11/7/2017Q3 2017($1.22)($1.27)($1.27)$3.60 million$4.28 millionN/A
8/8/2017Q2 2017($1.13)($1.27)($1.27)$4.06 million$3.51 millionN/A
5/9/20173/31/2017($1.14)($1.27)($1.27)$5.07 million$3.09 millionListen
2/27/2017Q4 2016($1.07)($1.36)($1.36)$5.00 million$5.69 millionListen
11/8/2016Q3 2016($0.95)($0.73)($0.73)$16.41 million$19.08 millionN/A
8/8/2016Q2 2016($1.12)($1.06)($1.06)$6.19 million$5.47 millionN/A
5/9/2016Q1 2016($0.96)($1.10)($1.10)$18.69 million$18.40 millionN/A
3/9/2016Q4 2015($1.42)($1.23)($1.23)($280,000.00) million$3.90 millionN/A
11/9/2015Q3 2015($1.33)($1.40)($1.40)$4.24 million$10.70 millionN/A
8/10/2015Q2 2015($0.29)($1.42)($1.42)$4.25 million$7.10 millionListen
5/7/2015Q1 2015($1.57)($1.29)($1.29)$7.55 million$20.40 millionN/A
3/10/2015Q4 2014($1.70)($2.02)($2.02)$2.01 million$1.30 millionN/A
11/6/2014Q3 2014($1.85)($1.72)($1.72)$1.08 million$6.34 millionN/A
8/13/2014Q2 2014($0.56)($1.83)($1.83)$1.01 million$2.97 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.